← Leaderboards
Vijay Bhoj
University Of Pennsylvania
$3,391,776
Attributed
$17,668,037
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2021–25$10M$7.5M$5M$2.5M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,668,037 · 4
By mechanism
U01$14,843,451 · 1
R01$2,458,961 · 2
R56$365,625 · 1
Top collaborators
- Ali Naji7 shared
- James F Markmann6 shared
- Alfred L. Garfall5 shared
- Carl H. June5 shared
- Michael C. Milone5 shared
- Chenyang Liu1 shared
- Marco Ruella1 shared
- Drew Weissman1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Aimee S Payne$10,136,122
- John R Stanley$7,319,814
- Ali Naji$46,943,355
- Therese Bittermann$2,559,387
- Nicola J Mason$7,580,948
Others in their field
Other Emerging Leaders on “Chimeric Antigen Receptor T Cells”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$21,497,910
- Crystal Mackall · Children'S Hosp Of Philadelphia$19,988,621
- Elizabeth Fox · St. Jude Children'S Research Hospital$8,840,232
- William H. Peranteau · Children'S Hosp Of Philadelphia$8,763,204
- Sandhya Vasan · Henry M. Jackson Fdn For The Adv Mil/Med$7,776,394
- Kole T Roybal · J. David Gladstone Institutes$7,404,890
Research focus
Chimeric Antigen Receptor T CellsImmunotherapyCellsImmuneClinical TrialsKidneyMolecularAntigensB-LymphocytesTransplantationChimeric Antigen ReceptorT Cell TherapyAllograftingIn VivoMemory B-LymphocyteT-LymphocyteAntibodiesCell TherapyKidney TransplantationCd19 GeneImmunityCar T Cell TherapyCohortEnd Stage Renal Failure
Grant awards (8)
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$4,303,502
U01 · FY2025 · AI
Immune repertoire remodeling following B cell-targeted CAR T cells for induction of renal allograft tolerance in non-human primates$1,648,086
R01 · FY2025 · AI
Selective B Cell Depletion Using Engineered T Cells As A Curative Treatment For Acquired Thrombotic Thrombocytopenic Purpura$810,875
R01 · FY2025 · HL · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$3,825,129
U01 · FY2024 · AI
Fibroblast Activation Protein as a Potential Diagnostic and Therapeutic Target to Treat Chronic Allograft Dysfunction$365,625
R56 · FY2024 · AI · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$764,364
U01 · FY2023 · AI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2022 · AI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2021 · AI